Kornimate/medical-research-clean huggingface dataset:
infantile - postoperative residual curarization - study

Conditions: Postoperative Residual Curarization; Neuromuscular Blockade; Neuromuscular Monitoring

Summary: the primary object of this study is, to investigate the current procedure of neuromuscular monitoring at a tertiary academic university medical center.

residual neuromuscular block is known to be a significant but frequently overlooked complication after the use of neuromuscular blocking agents. aim of this prospective, observational study is to detect the incidence and severity of residual paralysis at a tertiary academic german university medical center. methods: all infantile patients recieving neuromuscular blocking agents are included over a 12 week observational period. at the end of the operation procedure, directly prior to tracheal extubation a train-of-four ratio was assessed quantitatively by an independet observer using the tof watch sx monitor. data related to patient postoperative outcome were collected in the operating theatre, during the way to the postoperative care unit (pacu) and during the stay in the pacu: * incidence of residual paralysis * incidence of aspiration, bronchospasm, laryngospasm, oxygen desaturation, airway obstruction,

Eligibility criteria:
inclusion criteria: * general aneasthesia with muscle relaxation * children between 1 month to 18 years * endotracheal intubation due to surgical or diagnostical procedures exclusion criteria: * older than 18 years * local aneasthesia * regional aneasthesia * larynx mask * patient comes from icu * children who are not planned to be extubated
lumbar puncture and syphilis outcome

Conditions: Syphilis

Summary: treponema pallidum, the bacterium that causes syphilis, invades the central nervous system in about 40% of patients with syphilis. this happens early after infection. patients with neuroinvasion are at risk of developing serious neurological complications, including vision or hearing loss, stroke and dementia. because neuroinvasion can happen without symptoms, the only way to identify it is by performing a lumbar puncture (lp) to examine cerebrospinal fluid (csf).the overall hypothesis to be tested in this study is that a strategy of immediate lp, followed by therapy based on csf evaluation, results in better serological and functional outcomes in patients with syphilis who are at high risk for neuroinvasion.


Eligibility criteria:
inclusion criteria: 1. males and females age 18 years or older 2. current syphilis 3. primary language is english or english is a second language but patient self-describes as fluent in english 4. able to provide informed consent 5. if treated with benzathine penicillin g (bpg), it must have occurred less than 14 days before the entry visit (before the first visit if there is more than one entry visit) exclusion criteria: 1. provider plans neurosyphilis (ns) treatment regardless of whether the patient has an lumbar puncture (lp) 2. receipt of antibiotic treatment that would be effective for ns (for example, iv or intramuscular (im) beta-lactam antibiotics \[other than bpg\]) within one month before study entry; single dose of im ceftriaxone in the last month is not exclusionary 3. allergy to penicillin or lidocaine 4. contraindication to lp, including untreatable coagulation disorder, use of anticoagulants that cannot be temporarily discontinued, thrombocytopenia, focal neurological examination 5. other known cause of central nervous system (cns) infection in the last year, including that due to bacterial, fungal, protozoal or viral agents, such as tuberculosis, cryptococcus, toxoplasmosis or herpes zoster that could confound interpretation of csf results 6. unlikely to be able to comply with study requirements or complete the study, for example, planning to leave the area \< 6 months after enrollment 7. subjects will not be allowed to re-enroll in this study with a new episode of syphilis individuals who are unwilling to be randomized can choose lp or no lp. eligibility criteria for these individuals are: 1. 18 years of age or older 2. current syphilis infection 3. primary language is english or fluent in english 4. no contraindications to lp 5. have not received antibiotics within one month that would treat neurosyphilis
sym004 in combination with folfiri in metastatic colorectal cancer patients

Conditions: Metastatic Colorectal Cancer

Summary: this is a phase 1b/2a study investigating the safety and efficacy of sym004, an investigational medicinal product (imp), in combination with folfiri (chemotherapy) when administered every second week (q2w).

in the phase 1b (dose-escalation) portion of the trial, patients will be sequentially enrolled to dose-escalation cohorts until establishment of the maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of sym004 in combination with folfiri. the phase 2a (dose-expansion) portion of the trial is expected to begin after establishing the rp2d. note: in january 2017, the trial was terminated during phase 1b and enrollment was prematurely discontinued. the primary objective changed to assess the safety of the treatment combination; collection of data for secondary and exploratory objectives was omitted.

Eligibility criteria:
main inclusion criteria: 1. male or female, at least 18 years of age at the time of informed consent 2. eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 3. histologically or cytologically confirmed, locally advanced or metastatic colorectal cancer (crc) that is documented to be without kirsten rat sarcoma (kras) or neuroblastoma rat sarcoma (nras) gene mutations (i.e., tumors must express the kras and nras wild type \[wt\], exon 2, 3 and 4). 4. failed (defined as radiologic progression) treatment for locally advanced or metastatic disease with first-line combination therapy of oxaliplatin and a fluoropyrimidine, with or without bevacizumab, during treatment or \< 3 months after the last dose of first-line therapy and within \< 3 months of c1/d1. patients who discontinued first-line therapy due to toxicity may be enrolled provided progression occurred \< 6 months after the last dose of the first-line therapy regimen. or failed (defined as radiologic progression) adjuvant therapy with combination therapy of oxaliplatin and a fluoropyrimidine during treatment or within \< 6 months after the last dose of oxaliplatin and within \< 6 months of c1/d1. 5. eligible for folfiri 6. measurable disease according to recist v1.1 main exclusion criteria: 1. prior therapy with anti-egfr antibodies, anti-egfr small molecule inhibitors or irinotecan (cpt-11) 2. any antineoplastic agent (standard or investigational) within 4 weeks prior to c1/d1 3. significant gastrointestinal abnormalities 4. patients with a significant cardiovascular disease or condition 5. abnormal hematologic, renal or hepatic function

Keywords: metastatic colorectal cancer
intrahepatic chemotherapy to patients with non-resectable liver metastases from solid tumor

Conditions: Liver Metastasis

Summary: the purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases. if the patients have colorectal cancer and never had got chemotherapy the investigators will use oxaliplatin together with capecitabine. if the patient is k-ras wild type the investigators will add cetuximab. in patients who had received oxaliplatin or in patients with other cancers the investigators will use mitomycin and gemcitabine together with capecitabine.

two regiment are used: n.b. the two regiments will be reported separately 1. mitomycin + gemcitabine intrahepatic together with capecitabine. this treatment can be offered patients with solid tumors where all standard treatments have been used. the patients are not allowed to have extrahepatic disease. the purpose of the treatment are to prolonged life. 2. folfox where oxaliplatin is given intrahepatic each second time. the treatment are only for patients with colorectal cancer where cure is possible but resection straight ahead is not possible. the patients are allowed to have their colorectal cancer in situ for operation latter on. if the patients are kras wild-type, cetuximab are added.

Eligibility criteria:
inclusion criteria: * liver metastasis * solid tumor exclusion criteria: * poor performance

Keywords: oxaliplatin mitomycin gemcitabine intrahepatic liver metastasis response in liver metastasis downsized to operation
stress reduction in older women with stage ii, stage iii, or stage iv breast cancer

Conditions: Breast Cancer; Psychosocial Effects of Cancer and Its Treatment

Summary: rationale: transcendental meditation may be an effective way to decrease the amount of stress in older women with breast cancer. it is not yet known if transcendental meditation is more effective than basic breast cancer education in improving quality of life. purpose: this randomized clinical trialstudies stress reduction in improvingquality of life in older women with stage ii, stage iii, or stage iv breast cancer.

objectives: * compare the effects of active stress reduction with transcendental meditation vs basic breast cancer education on quality of life and survival time in older women with stage ii, iii, or iv breast cancer. * determine behavioral mechanisms that may mediate the effects of stress reduction on survival in these patients. * determine baseline variables that contribute to predicting survival time in these patients. outline: this is a randomized, single blind (to medical staff), multicenter study. patients are stratified according to age and participation in support groups. patients with stage iv disease are also stratified according to type of metastases (visceral vs non-visceral) and timing of metastases (first diagnosis vs recurrence). patients are randomized to 1 of 2 treatment arms. * arm i: patients receive usual medical care and instruction on stress reduction using transcendental meditation (tm), which involves a standard 7-step course. patients attend training for approximately 1-1.5 hours per session for a total of 6 sessions over 1 week, while receiving usual medical care. patients then practice tm twice a day for 20 minutes. patients attend group meetings for approximately 90 minutes once or twice monthly for 6 months to ensure proper technique and understanding. * arm ii: patients receive usual medical care and basic literature on breast cancer. quality of life is assessed at baseline and then every 6 months for up to 3 years. patients are followed monthly for up to 2.5 years. projected accrual: approximately 166 patients (83 per treatment arm) will be accrued for this study within 6 months.

Eligibility criteria:
disease characteristics: * diagnosis of stage ii, iii, or iv breast cancer * no brain or cns metastases * hormone receptor status: * not specified patient characteristics: age: * 55 and over sex: * female menopausal status: * not specified performance status: * ecog 0-2 life expectancy: * more than 3 months hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no non-cancer life-threatening illness * no history of major psychiatric disorders * no drug abuse dependency disorder prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified

Keywords: stage ii breast cancer stage iv breast cancer stage iiia breast cancer stage iiib breast cancer psychosocial effects of cancer and its treatment
evaluation of parents' knowledge about infant teething

Conditions: Signs and Symptoms

Summary: many children may have general disorders such as sleep disorders, lack of appetite, fever, diarrhea, vomiting, coughing and respiratory problems during tooth eruption.these symptoms usually occur in6-36 monthchildren. the emergent symptoms don't affect not only children but also parents try to find solutions to these symptoms. parents' knowledge level and their way trying finda solution to these symptoms may differ. the aim of this study is to evaluate the perceptions of parents towards the teething signs and symptoms of their children aged 6-36 months-old.as a result of the research, it is aimed to organize educational programs for families by increasing the knowledge level of parents about teething symptoms.

the study is being carried out in istanbul university department of pediatric dentistry, period between september 2021 - august 2022 following the ethics committee approval 2021/34. patient parents are informed about the study and the written informed consents are obtained from parents of all participants included in the study. the questionnaireis conducted face-to-face. parents with children between 6-36 months-oldwho has been applying to the department of pedodontics at istanbul university faculty of dentistry are asked to complete the questionnaire consisting of 55 questions. questionnaire: 8 questions to find out the sociodemographic characteristics, 6 questions to find out the characteristics of the baby 6 questions to find out the general knowledge about children's teething 23 questions to find outthe teething symptoms that are seen in their babies 3 questions to find out the timing of the symptoms 9 questions to find out the parents practices in managing teething problems. questionnaire responses are being recorded. the answers will be evaluated with statistical analyses. detailed analyses of responses will be carried out according to sociodemographic characteristics, family structures and educational levels of parents.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * parents who have 6-36 months old child * presence of parents who can adequately answer the questionnaire questions exclusion criteria: * not willing to participte in the study * parents with no children for the specific age group * in case of not being able to answer the questionnaire questions from the parents

Keywords: signs and symptoms tooth eruption child
therapeutic adherence in uncontrolled arterial hypertension

Conditions: Treatment Adherence

Summary: in hypertension, highly prevalent, up to 10-15% of hypertensive patients have uncontrolled blood pressure despite being treated with ≥3 drugs, which is known as resistant hypertension. resistant arterial hypertension, together with difficult-to-control hypertension, has a worse cardiovascular prognosis than controlled hypertension. in addition, data on therapeutic adherence in arterial hypertension show that 1 in 2 hypertensive patients do not fully or partially comply with the indicated therapeutic prescription. the determination of antihypertensive drugs or their metabolites in urine seems to be a good indicator of therapeutic adherence. on the other hand, the implementation of a specific program to improve knowledge of the disease and its risks and promote therapeutic adherence could improve the control of hypertension and reduce the associated morbidity and mortality.

objective: to assess whether the implementation of a specific action plan to improve adherence for 3 months results in reduced peripheral 24h-systolic blood pressure (sbp) in patients with resistant hypertension (rh) or uncontrolled hypertension with 2 antihypertensive drugs. method: interventional, prospective, randomized, controlled, parallel groups, open study of a cohort of 150 consecutively recruited patients with rh (office sbp ≥140mmhg and/or diastolic blood pressure ≥90mmhg despite treatment with ≥3 drugs at appropriate doses, one diuretic) or patients with uncontrolled hypertension with 2 antihypertensive drugs, with ambulatory 24h-bp ≥130 and / or 80mmhg. the partially or completely non-adherent patients (confirmed by determination of antihypertensive drugs in urine) will be randomized (1: 1) to receive a specific program to improve adherence (intervention group) or routine follow-up (control group), with office bp measurement and determination of antihypertensive drugs in urine at pre-randomization, 3, 6 and 12 months; peripheral and central 24h-ambulatory bp monitoring will be performed at pre-randomization, at 3 and 12 months.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years * diagnosis of resistant hypertension with treatment superior to 3 drugs at maximum dose, one of them being a diuretic * uncontrolled hypertension treated with 2 drugs at the maximum effective doses tolerated * the prescribed treatment must be stable for the last 2 months * given informed consent exclusion criteria: * secondary arterial hypertension * pregnant women * impossibility to perform a 24-hour blood pressure monitoring, or poor quality results. * recent history of major vascular episode * patients receiving treatment with barnidipino / felodipine / lercanidipine / manidipine / nifedipine / verapamil / eplerenone
tapering of analgosedation and occurrence of withdrawal syndrome in paediatric intensive care treatment

Conditions: Drug Withdrawal Symptoms; Critical Care; Child

Summary: the study is a prospective interventional study with three main aims: 1. describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2. test whether implementation of an algorithm for tapering of analgosedation changes the frequency and severity of withdrawal symptoms in the same population. 3. investigate how the health care providers experience having to adhere to such an algorithm.

patients \< 18 years of age treated in an intensive care unit for 5 days or more with infusion of opioids and/or benzodiazepines, are eligible for inclusion. patients are included at the time tapering of these drugs is initiated. part one of the study is observational. drugs administered, complications, comfort score and wat-1 (withdrawal assessment tool-1) score is recorded. before part two of the study, an algorithm for tapering of analgosedation is implemented, and the data set is obtained as in part one. for part three of the study, focus group interviews will be used.

Eligibility criteria:
inclusion criteria: * \< 18 years * treated in picu * infusion of opioids and/or benzodiazepins for 5 days or more. exclusion criteria: * neuromuscular disease * cognitive/neurological disturbance caused by a disease * multiple disabilities
coordinating pragmatic primary care population management for obesity

Conditions: Obesity; Cardiovascular Risk Factor

Summary: the c3po pilot and feasibility study uses a rigorous, mixed-method research design to provide information needed to refine and implement a technology-mediated primary care outreach intervention approach before conducting a larger and more definitive future intervention trial.

this study will implement and evaluate a pragmatic and generalizable framework for population management of obesity by the primary care sector. with patient and other stakeholder input, the c3po intervention will be designed to leverage existing primary care professionals and technologies to implement a scalable framework for population obesity management that coordinates primary care services with extant intensive lifestyle interventions in community settings to achieve wider reach and population-level effectiveness. a rigorous, mixed-method pilot and feasibility study will provide critical information needed to optimize the intervention design and prepare us for a larger and definitive future trial.

Eligibility criteria:
inclusion criteria: * bmi ≥ 27 kg/m2 * ≥ 1 cvd risk condition (hypertension, dyslipidemia, prediabetes or type 2 diabetes) * registered in northwestern medical group's epiccare mychart patient portal * received and completed mychart survey of weight loss interest * affirms interest in weight loss goal setting and receiving additional resource information and electronic scale. exclusion criteria: * evidence of hospitalization in past 30 days * most recent blood pressure \>180/105 * cancer (non-skin) treatment within the past 2 years * encounter diagnosis for hypoglycemia in past 30 days * actively receiving care from the bariatric surgery service or a bariatric medication order in the past 100 days

Keywords: overweight obesity prediabetes type 2 diabetes hypertension dyslipidemia cardiovascular risk factor adult primary care
a non-interventional pilot study to explore the skin microbes in skin cancer

Conditions: Skin Cancer; Melanoma (Skin); Squamous Cell Carcinoma; Basal Cell Carcinoma; Microbiome

Summary: this study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.

the human skin microbiome is a complex, interconnected web of microbes, living in a symbiotic relationship with their host. there are greater than ten times more bacteria on our bodies than there are human cells, all in a delicate and ever-changing balance to maintain a healthy skin microbiome. when this balance is disrupted, a condition known as dysbiosis, disease can occur. there is still a debate over whether dysbiosis is a cause of disease or a symptom of it. naturally, since the microbiome has such a profound impact on human health, we want to study and learn as much about the microbiome as possible. by correlating this data with medical records for the patient's skin cancer, connections may begin to be drawn between organisms present in the microbiome of the skin microbiome, and skin cancer. much like fingerprints, no microbiome is identical therefore the only chance we have at understanding disease is by looking at the skin microbiome and comparing the microorganisms on a patient with skin cancer biopsy and non-skin cancer biopsy.

Eligibility criteria:
inclusion criteria: * signed informed consent * 18 years of age or older * diagnosis of skin cancer, both melanoma and non-melanoma * able/willing to have a skin punch biopsy in a non-cancerous location exclusion criteria: * unable/unwilling to sign informed consent * inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.
"comparison of the effectiveness of conventional radiofrequency thermocoagulation and chemical ablation with phenol on articular branches of femoral and obturator nerves in chronic hip pain"

Conditions: Chronic Pain

Summary: "in our study, we aimed to compare the effects of conventional radiofrequency thermocoagulation applied to the articular branches of the femoral and obturator nerves with chemical ablation using phenol on hip pain."

"our study is designed as a double-blind, prospective randomized controlled trial. blinding will be ensured by keeping the researcher performing pain diary follow-ups unaware of which procedure was applied to each patient. patients will be randomized using computer-assisted methods. following approval from the hospital ethics committee, clinical trial registration will be conducted. from 2024 to 2025, patients presenting with chronic hip pain to the department of algology at adu faculty of medicine will be divided into two groups. in group 1, chemical ablation of the femoral and obturator nerve branches with phenol under ultrasound guidance will be performed. in group 2, conventional radiofrequency thermocoagulation of the articular branches of the femoral and obturator nerves under ultrasound guidance will be applied. during the study, pain intensity will be assessed using the numerical rating scale (nrs) at baseline, 2 hours post-procedure, and at 1 month and 3 months post-procedure for both group 1 and group 2. the womac scale will be used to evaluate their functional capacity."

Eligibility criteria:
inclusion criteria: be older than 18 years old. written consent must be obtained. have had chronic hip pain for more than 3 weeks. - exclusion criteria: major psychiatric illness presence of lumbar radicular pain or referred pain in the patient patients using anticoagulant agents patients with infection in the area where the procedure will be performed those with allergy to local anesthetics those allergic to phenol or betamethasone pregnant women scheduled for surgery -

Keywords: radiofrequency thermocoagulation phenol chemical ablation